Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall response

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

Roy S. Herbst, Dong‐Wan Kim, Enriqueta Felip et al. · The Lancet · 2015 · 6.5K citations

Medicine, Oncology, Pharmacology +14

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

Edward B. Garon, Naiyer A. Rizvi, Rina Hui et al. · New England Journal of Medicine · 2015 · 6.2K citations · Full text

Medicine, Oncology, Pharmacology +17

Pembrolizumab versus Ipilimumab in Advanced Melanoma

Caroline Robert, Jacob Schachter, Georgina V. Long et al. · New England Journal of Medicine · 2015 · 5.8K citations · Full text

Life Sciences, Oncology, Pharmacotherapy +17

Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

Haidong Dong, Scott E. Strome, Diva R. Salomão et al. · Nature Medicine · 2002 · 5K citations

Life Sciences, Immunology, Oncology +17

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade

Yoshiko Iwai, Masayoshi Ishida, Yoshimasa Tanaka et al. · Proceedings of the National Academy of Sciences · 2002 · 3.2K citations

Life Sciences, Immunology, Oncology +17